On November 11, Jiaying Pharmaceutical closed at 7.23 yuan today, up 5.70%, and the scrolling P / E ratio PE (the proportion of the current stock price to the total earnings per share in the first four quarters) reached 298.62 times.New low.
From the perspective of the industrys price -earnings ratio ranking, the companys price -earnings ratio of the Chinese medicine industry is 46.60 times, the industry is 26.83 times, and Jiaying Pharmaceutical ranks 70th.
On the message, Jiaying Pharmaceutical received an investigation on an institution of investor online questions on September 12.Xiao Qiaoxia, Shi Junping, chief financial officer.
Guangdong Jiaying Pharmaceutical Co., Ltd. is a professional Chinese medicine production enterprise integrating R & D, production and sales.The companys main products are dual -material laryngeal wind, double -ingredient laryngeal style tablets, heavy spiritual slices, silver -thorough detoxification particles, orange red phlegm cough particles, linked detoxification capsules, bone seven clicks, bone -connected capsules, sparse wind active tablets, Meridsenal blood circulation, anti -inflammatory bile tablets, golden chrysanthemum tea particles, strong waist and kidney pills, solid essence ginseng pills, Gui Furazhong pills, stomach pain tablets, vomiting belly pain capsules.The companys leading product double -material laryngeal wind scattered and heavy spiritual films have been protected by national traditional Chinese medicine, and they have won the title of "Guangdong Famous Brand Product", which has a certain brand influence.In 2022, the exclusive variety of Jinsha Pharmaceuticals was selected as one of the top ten key products of the biopharmaceutical industry in Hunan Province by Hunan Provincial Pharmaceutical Supervision Department.The brand image of Sands Pharmaceutical is enhanced.
The latest performance shows that in the third quarter of 2024, the company realized operating income of 260 million yuan, a year-on-year-31.18%; net profit was 2.873 million yuan, a year-on-year-88.46%, sales gross profit margin, and sales gross margin.57.42%.
This article comes from: the financial industry
Author: market
